KEY POINTS
- These GEC-ESTRO Gastrointestinal Working Group consensus recommendations establish a standardized clinical and technical framework for image-guided interstitial high-dose-rate brachytherapy of primary and metastatic liver tumors. Developed by an international expert panel, the document addresses patient selection, image-guided catheter implantation, target and OAR delineation, dose prescription, treatment planning, toxicity management, and follow-up. The recommendations apply to selected patients with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, colorectal liver metastases, and other secondary liver malignancies, particularly when resection or thermal ablation is unsuitable.
- Patient selection must account for liver function, coagulation status, and procedural risks. The consensus recommends multidisciplinary evaluation and preprocedural imaging using multiphasic CT and preferably hepatocyte-specific contrast-enhanced MRI. Suggested coagulation prerequisites include INR ≤1.5, platelet count >50 × 10⁹/L, and PTT <50 seconds, assessed within one week of treatment. Advanced cirrhosis, ascites, and ongoing anticoagulation are relative contraindications, while poor performance status (ECOG ≥3) or severe hepatic dysfunction (Child-Pugh C) may preclude treatment. Patients with biliodigestive anastomoses, papillotomy, or biliary involvement require particular attention to infection risk.
- Two principal image-guided catheter implantation approaches are described. Direct implantation involves advancing a 6F brachytherapy catheter under CT fluoroscopy, while the Seldinger technique uses an initial 17–18G needle, guidewire, and angiographic sheath to introduce a flexible 6F catheter. The latter facilitates puncture-tract sealing after treatment and can be used with MRI guidance. CT, ultrasound, and MRI are all acceptable guidance modalities depending on tumor visibility and institutional expertise, while treatment is generally delivered using an iridium-192 remote afterloading system.
- Target definition and dose reporting are standardized, while treatment margins remain individualized. The GTV includes visible tumor, and the CTV incorporates a potential microscopic extension margin, typically 0–5 mm, with no universally agreed expansion. An additional PTV margin is generally not applied (CTV = PTV). The consensus recommends reporting D100% and D98% as standard target metrics, supplemented by D95%, D90%, D50%, and V150%, V200%, and V300% for more detailed characterization of highly heterogeneous HDR dose distributions. The intended prescription should ideally cover the complete reported target volume.
- Table 2 provides histology-specific single-fraction dose-planning aims. Suggested D100% prescription doses are 25 Gy for colorectal cancer liver metastases, 20 Gy for cholangiocarcinoma, 15 Gy for hepatocellular carcinoma, and 20 Gy for other liver metastases. These values represent consensus-based planning objectives informed by published liver HDR brachytherapy experience, not randomized evidence establishing universal optimal doses. Patient-specific prescription and target coverage should be adjusted when required by adjacent critical structures or impaired hepatic reserve.
- The consensus also specifies quantitative OAR constraints for single-fraction treatment. For the esophagus, stomach, duodenum, small bowel, and large bowel, suggested constraints are D0.1cm³ ≤15 Gy and D1cm³ ≤12 Gy. For the main bile duct, corresponding limits are 20 and 18 Gy, while spinal canal limits are 12 and 10 Gy. Healthy liver constraints include V10Gy <33% and V5Gy <66% of uninvolved liver volume. The panel explicitly prioritizes compliance with established OAR dose limits over complete target coverage when the two objectives conflict.
- Available clinical evidence supports local efficacy but remains predominantly nonrandomized. Among reported HCC series, one 146-patient cohort achieved local control of 87%, 75%, and 73% at 12, 24, and 36 months, respectively. In a separate safety series involving 343 procedures in 192 patients, major complications occurred in 4.1%, including severe hemorrhage in 1.46% and gastroduodenal ulceration in 0.87%. Follow-up imaging is recommended at intervals of no more than three months, preferably using hepatocyte-specific contrast-enhanced liver MRI. No randomized evidence establishes superiority over contemporary SBRT or other liver-directed approaches across the included histologies.
CLINICAL TAKEAWAY
The GEC-ESTRO recommendations provide a practical framework for delivering interstitial HDR brachytherapy to selected liver tumors, including explicit dose prescriptions, OAR constraints, catheter techniques, and standardized reporting parameters. These recommendations are particularly relevant for centers implementing or refining liver-directed brachytherapy, but the supporting evidence is heterogeneous and largely observational. Dose selection must remain individualized, and the proposed constraints should be interpreted within the specific single-fraction interstitial brachytherapy setting rather than transferred directly to external-beam SBRT.